Related Experiment Video
Updated: Jun 5, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
[Fabry disease among hypertrophic cardiomyopathy of genetic origin]
P Bouvagnet1, G Millat, R Rousson
1Laboratoire Cardiogénétique, Groupe Hospitalier Est, Hospices Civils de Lyon, Lyon, France. Patrice.Bouvagnet@chu-lyon.fr
Insights
Primary hypertrophic cardiomyopathy, often genetic, can be caused by Fabry disease. Screening for Fabry disease is crucial in unexplained hypertrophic cardiomyopathy cases, especially in males and females with affected relatives.
Area of Science:
- Cardiology
- Genetics
- Metabolic Diseases
Background:
- Primary hypertrophic cardiomyopathy (HCM) affects 1 in 500 individuals, frequently linked to sarcomeric protein gene mutations (MYBPC3, MYH7, TNNI3, TNNT2).
- Fabry disease, a lysosomal storage disorder, can manifest as a cardiac variant with exclusive or near-exclusive cardiac involvement.
Observation:
- Fabry disease-associated HCM is often unspecific, yet accounts for approximately 6% of male HCM cases.
- Diagnosis in females is feasible through myocardial biopsy screening for specific lesions.
- A case presented with common HCM and specific ECG abnormalities (ST depression, T-wave inversion), with a family history suggesting X-linked inheritance.
Findings:
- An isolated, common hypertrophic cardiomyopathy may indicate an underlying Fabry disease.
- Systemic enzyme screening is recommended for male HCM patients, excluding father-to-son transmission.
- Female HCM patients warrant screening via family history or GLA gene sequencing.
Implications:
- Considering Fabry disease in HCM cases without apparent causes improves diagnostic yield.
- Early diagnosis of Fabry disease enables timely intervention and management, potentially altering disease progression.
- This highlights the importance of a comprehensive diagnostic approach for hypertrophic cardiomyopathy.
Abstract:
Primary hypertrophic cardiomyopathy is a relatively frequent disease (1/500) which results from a mutation in a gene encoding a sarcomeric protein. In a series of 184 cases, nearly half (46 %) were secondary to a mutation in one of the 4 following genes : MYBPC3, MYH7, TNNI3, TNNT2. In Fabry disease, an exclusive or nearly exclusive cardiac expression is possible and referred to as "cardiac variant". The hypertrophic cardiomyopathy of Fabry disease is usually unspecific. Two series reported a prevalence of Fabry disease of about 6% among male cases. An Italian series of 34 female cases with hypertrophic cardiomyopathy demonstrated that it was feasible to diagnose Fabry disease in females by screening for specific lesions in myocardial biopsies. We detected a patient who initially presented with a common hypertrophic cardiomyopathy except that his ECG showed depression of ST segment and inversion of T wave in leads D1, VL and in precordial leads. The family history revealed several affected relatives and female carriers. In conclusion, an isolated common hypertrophic cardiomyopathy may be secondary to Fabry disease. Male patients should be screened systemically for enzyme defect except in cases of father-to-son transmission. In females, an affected male relative should be searched for screening or the GLA gene should be sequenced. It is important to think about a putative Fabry disease in cases with hypertrophic cardiomyopathy not associated with any obvious cause.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure II: Pathophysiology
Rheumatic Heart Disease I: Introduction

